Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisEric L. Simpson, Marius Ardeleanu, Thomas Bieber et al.|New England Journal of Medicine|2016Cited by 2k
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trialDiamant Thaçi, Marius Ardeleanu, Eric L. Simpson et al.|The Lancet|2015Cited by 566
Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase<scp>III</scp>trialsEric L. Simpson, Kristian Reich, Lisa A. Beck et al.|British Journal of Dermatology|2020Cited by 377
Genome-Wide Scan on Total Serum IgE Levels Identifies FCER1A as Novel Susceptibility LocusStephan Weidinger, Thomas Illig, Christian Gieger et al.|PLoS Genetics|2008Cited by 292
Putative association of a <i>TLR9</i> promoter polymorphism with atopic eczemaNatalija Novak, Stephan Weidinger, Chunfeng Yu et al.|Allergy|2007Cited by 174